OR1L3

Across TCGA pan-cancer cohorts, OR1L3 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated OR1L3 data layer compared with 10 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher OR1L3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated OR1L3 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

HNSC, LUSC, and UCEC are the cancer types where OR1L3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.220	0.752	<.001	24	view →
LUSC	OS	Median	III,IV	0.112	0.664	.003	21	view →
UCEC	DFS	Median	All	1.000	0.634	.022	18	view →
LIHC	DFS	Median	All	0.041	0.556	<.001	12	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

OR1L3–HNSC (OS)

Open the HNSC breakdown →